AbCellera Biologics Operating Income

AbCellera Biologics (ABCL) currently reports a operating income of $-230M as of June 2026. That compares with $-320M in the prior-year period — up 29.9% year over year. Use the charts on this page to explore AbCellera Biologics's operating income history and peer comparisons.

AbCellera Biologics's operating income increased from $-320M to $-230M — a 29.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AbCellera Biologics reported $-230M in operating income as of June 2026. That compares with $-320M in the prior-year period — up 29.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-230M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AbCellera Biologics, and consider following ABCL for alerts when major investors trade the stock.